Termination of the European Bendamustine Technology Out-Licensing Agreement with Mundipharma Group
An individual matter concerning the European technology out-licensing agreement for bendamustine hydrochloride with Mundipharma Group, which ended upon expiration of its term in September 2021 after the contract term was changed.
Companies1How many companies write about this.
Threads1One company can carry more than one thread here.